LivaNova PLC (LIVN)
NASDAQ:LIVN
Top Page
LivaNova
(NASDAQ:LIVN)
Select Model
Select Model
Rating:68Neutral
Price Target:
$67.00
▲(3.62% Upside)
Action:ReiteratedDate:02/25/26
The score is driven primarily by solid cash generation and supportive balance-sheet trends despite notable earnings volatility (including a 2025 net loss). Technicals are constructive with the stock in an uptrend, while valuation is weakened by the negative P/E and lack of dividend data. Earnings-call guidance and sentiment are generally positive but moderated by supply constraints and a significant planned cash payment assumption.
Positive Factors
Consistent cash generation
Sustained positive operating and free cash flow through 2021–2025 (OCF ~ $254M, FCF ~ $173M in 2025) provides durable internal funding for R&D, capex and debt repayments. Reliable cash conversion underpins balance-sheet flexibility and supports multi-year product investment and rollout plans.
Negative Factors
Earnings volatility / 2025 net loss
Intermittent profitability, including a large 2025 net loss despite revenue growth, signals below-the-line or one-time pressures that can erode retained earnings. Persistent earnings volatility undermines long-term margin predictability and constrains reinvestment or dividend capacity during adverse cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent cash generation
Sustained positive operating and free cash flow through 2021–2025 (OCF ~ $254M, FCF ~ $173M in 2025) provides durable internal funding for R&D, capex and debt repayments. Reliable cash conversion underpins balance-sheet flexibility and supports multi-year product investment and rollout plans.
Read all positive factors
LivaNova (LIVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.54B
Dividend YieldN/A
Average Volume (3M)906.73K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth8.97%
EPS Growth-1024.86%
CountryUS
Employees2,900
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.86
Shares Outstanding54,689,877
10 Day Avg. Volume645,040
30 Day Avg. Volume906,726
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.79
Price to Sales (P/S)2.42
P/FCF Ratio19.36
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue2.43
Enterprise Value/Gross Profit3.57
Enterprise Value/Ebitda-27.99
Forecast
1Y Price Target
$80.13Price Target Upside23.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)4.21
Revenue Forecast (FY)$1.49B
LivaNova Business Overview & Revenue Model
Company Description
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment...
How the Company Makes Money
LivaNova makes money primarily by selling medical devices and recurring-use products used alongside those devices. A significant portion of revenue is generated in its Cardiopulmonary segment through sales of heart-lung machine platforms and, impo...
LivaNova Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call communicated solid commercial and financial momentum: double-digit growth in core businesses, margin expansion, stronger cash and materially lower debt, meaningful Medicare reimbursement improvements for epilepsy, and multiple clinical/regulatory milestones (FDA digital platform approval, OSPREY data, OSA PMA timeline). Offsetting items include supply constraints for oxygenators, increased R&D and capex for strategic launches, a significant assumed SNIA cash payment in 2026, and conservative near-term guidance reflecting component constraints and tougher comps. Overall, the company appears well-positioned for medium-term growth while prudently managing near-term operational and cash assumptions.Positive Updates
Top-line Growth and Segment Performance
Q4 revenue of $361M, up 9.5% on a constant currency and organic basis; full-year cardiopulmonary revenue $785M, +13% YoY; cardiopulmonary Q4 revenue $207M, +10% YoY; epilepsy full-year revenue growth 6% and Q4 epilepsy +9% YoY with broad regional strength (Europe & RoW +17% Q4; U.S. epilepsy +8% Q4).
Negative Updates
Supply Constraints and Manufacturing Pressure
Strong demand for oxygenators outpaced supply in 2025; third-party component constraints prompted conservative oxygenator output assumptions for 2026 and required capacity expansion and supplier partnerships.
Read all updates
Q4-2025 Updates
Positive
Negative
Top-line Growth and Segment Performance
Q4 revenue of $361M, up 9.5% on a constant currency and organic basis; full-year cardiopulmonary revenue $785M, +13% YoY; cardiopulmonary Q4 revenue $207M, +10% YoY; epilepsy full-year revenue growth 6% and Q4 epilepsy +9% YoY with broad regional strength (Europe & RoW +17% Q4; U.S. epilepsy +8% Q4).
Read all positive updates
Company Guidance
LivaNova guided full-year 2026 consolidated revenue growth of 6–7% (constant currency), with cardiopulmonary revenue expected to grow 7–8% and epilepsy 5.5–6.5%; adjusted diluted EPS is forecast at $4.15–$4.25 (≈8% growth at the midpoint) on roughly 56 million adjusted diluted weighted average shares, and an adjusted effective tax rate of ~23%. They expect adjusted free cash flow of $160–$180 million (which assumes $120 million of capital spend) and included a planned ~ $400 million third‑quarter SNIA payment—flagged as causing a $0.06 unfavorable impact to adjusted free cash flow. For context, Q4 revenue was $361 million (up 9.5% cc/organic), Q4 cardiopulmonary was $207 million (full‑year cardiopulmonary $785 million, +13%), adjusted gross margin was 68%, adjusted operating margin 18% in Q4, full‑year 2025 adjusted free cash flow was $183 million, cash at year‑end was $636 million and total debt $377 million; operational priorities cited include reaching ~80% Essence penetration of new HLM placements by 2026 and continued investment in OSA, next‑gen oxygenator scale‑up and epilepsy Connected Care.LivaNova Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
68
Positive
Cash Flow
74
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.39B | 1.25B | 1.15B | 1.02B | 1.04B |
| Gross Profit | 939.90M | 870.87M | 771.25M | 707.23M | 705.99M |
| EBITDA | -129.50M | 202.52M | 38.48M | 30.90M | -6.33M |
| Net Income | -242.50M | 63.23M | 17.55M | -86.25M | -135.82M |
Balance Sheet | |||||
| Total Assets | 2.61B | 2.51B | 2.43B | 2.29B | 2.20B |
| Cash, Cash Equivalents and Short-Term Investments | 635.60M | 428.86M | 266.50M | 214.17M | 207.99M |
| Total Debt | 473.30M | 676.77M | 640.40M | 580.43M | 286.70M |
| Total Liabilities | 1.41B | 1.19B | 1.15B | 1.09B | 906.31M |
| Stockholders Equity | 1.20B | 1.32B | 1.28B | 1.21B | 1.29B |
Cash Flow | |||||
| Free Cash Flow | 173.20M | 135.93M | 39.93M | 43.40M | 77.07M |
| Operating Cash Flow | 254.30M | 183.04M | 74.91M | 69.90M | 102.54M |
| Investing Cash Flow | -72.90M | -48.16M | -40.33M | -38.40M | 36.90M |
| Financing Cash Flow | -285.70M | 18.55M | 21.48M | 280.10M | -181.48M |
LivaNova Technical Analysis
Positive
64.66
Price Trends
64.90
Negative
63.28
Positive
57.03
Positive
Market Momentum
-0.18
Negative
53.82
Neutral
66.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LIVN, the sentiment is Positive. The current price of 64.66 is above the 20-day moving average (MA) of 62.59, below the 50-day MA of 64.90, and above the 200-day MA of 57.03, indicating a neutral trend. The MACD of -0.18 indicates Negative momentum. The RSI at 53.82 is Neutral, neither overbought nor oversold. The STOCH value of 66.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LIVN.
LivaNova Risk Analysis
LivaNova disclosed 34 risk factors in its most recent earnings report. LivaNova reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LivaNova Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $1.55B | 25.04 | 17.36% | ― | 29.47% | 23.24% | |
68 Neutral | $3.54B | -13.83 | -21.49% | ― | 8.97% | -1024.86% | |
67 Neutral | $3.68B | 21.73 | 53.88% | ― | 41.20% | 173.53% | |
66 Neutral | $3.01B | 26.50 | 6.05% | ― | 7.81% | -26.32% | |
66 Neutral | $1.53B | 18.63 | 21.07% | ― | 16.81% | 34.90% | |
59 Neutral | $1.73B | 211.68 | 2.44% | ― | 9.81% | -1067.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
LIVN
LivaNova
64.66
28.94
81.02%
AORT
Artivion
36.06
12.11
50.56%
ITGR
Integer Holdings
87.48
-28.89
-24.83%
UFPT
Ufp Technologies
200.49
-11.43
-5.39%
INSP
Inspire Medical Systems
53.38
-100.43
-65.29%
TMDX
TransMedics Group
109.36
33.95
45.02%
LivaNova Corporate Events
Executive/Board Changes
LivaNova Announces Chief Legal Officer Resignation and Succession
Neutral
Jan 14, 2026
On January 12, 2026, LivaNova PLC announced that Michael Hutchinson has resigned as Senior Vice President, Chief Legal Officer and Company Secretary, with his last day set for January 26, 2026, as he departs to pursue another opportunity. The comp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.